瓦莫罗龙对比安慰剂和泼尼松在杜氏肌营养不良男孩中的疗效与安全性:一项随机临床试验
这项随机、双盲、安慰剂和泼尼松对照的24周多中心试验纳入133名4至7岁以下基因确诊、未用过糖皮质激素的杜氏肌营养不良男孩,评估瓦莫罗龙2 mg/kg/天和6 mg/kg/天对比安慰剂和泼尼松0.75 mg/kg/天的疗效与安全性。瓦莫罗龙6 mg/kg/天组从仰卧位站起速度较安慰剂显著改善(最小二乘均值0.05 m/s vs -0.01 m/s,95%CI 0.02-0.10,P=0.002),并达到前4个序贯次要终点;泼尼松组身高百分位下降而瓦莫罗龙组未下降,骨转换标志物仅泼尼松组下降;所有3个治疗组肾上腺功能不全发生率均增加。
要点
- 瓦莫罗龙6 mg/kg/天组从仰卧位站起速度较安慰剂显著改善(P=0.002)。
- 泼尼松组身高百分位下降,瓦莫罗龙6 mg/kg/天组未下降(P=0.02)。
- 骨转换标志物仅泼尼松组下降,瓦莫罗龙组未下降。
核心结论
- 在这项关键随机临床试验中,瓦莫罗龙在24周治疗期内对杜氏肌营养不良男孩显示有效且安全。
- 瓦莫罗龙可能成为比泼尼松更安全的替代选择,该病长期使用糖皮质激素为标准治疗。
研究设计与样本
- 随机、双盲、安慰剂和泼尼松对照的24周临床试验,随访24周,2018年6月29日至2021年2月24日进行。
- 多中心研究,纳入11个国家33个转诊中心,对象为4至7岁以下基因确诊、既往未使用糖皮质激素的杜氏肌营养不良男孩。
- 133名男孩入组(平均[SD]年龄5.4[0.9]岁),121名随机分配至治疗组,114名完成24周治疗。
- 4组:安慰剂;泼尼松0.75 mg/kg/天;瓦莫罗龙2 mg/kg/天;瓦莫罗龙6 mg/kg/天。
主要发现
- 主要终点:瓦莫罗龙6 mg/kg/天组从仰卧位站起速度较基线至第24周变化的最小二乘均值[SE]为0.05[0.01] m/s,安慰剂组为-0.01[0.01] m/s(95%CI 0.02-0.10,P=0.002)。
- 达到前4个序贯次要终点:瓦莫罗龙2 mg/kg/天组从仰卧位站起速度对比安慰剂;瓦莫罗龙6 mg/kg/天组6分钟步行试验对比安慰剂;瓦莫罗龙2 mg/kg/天组6分钟步行试验对比安慰剂;瓦莫罗龙6 mg/kg/天组跑/走10米速度对比安慰剂。
- 身高百分位在泼尼松组下降而瓦莫罗龙组未下降(基线变化[SD]:泼尼松-1.88[8.81]百分位 vs 瓦莫罗龙6 mg/kg/天组+3.86[6.16]百分位;P=0.02)。
- 骨转换标志物在泼尼松组下降,瓦莫罗龙组未下降。
- 基线时杜氏肌营养不良男孩显示低促肾上腺皮质激素刺激皮质醇和高肾上腺功能不全发生率;所有3个治疗组均导致肾上腺功能不全增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Corticosteroidal anti-inflammatory drugs are widely prescribed but long-term use shows adverse effects that detract from patient quality of life. OBJECTIVE: To determine if vamorolone, a structurally unique dissociative steroidal anti-inflammatory drug, is able to retain efficacy while reducing safety concerns with use in Duchenne muscular dystrophy (DMD). DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo- and prednisone-controlled 24-week clinical trial, conducted from June 29, 2018, to February 24, 2021, with 24 weeks of follow-up. This was a multicenter study (33 referral centers in 11 countries) and included boys 4 to younger than 7 years of age with genetically confirmed DMD not previously treated with corticosteroids. INTERVENTIONS: The study included 4 groups: placebo; prednisone, 0.75 mg/kg per day; vamorolone, 2 mg/kg per day; and vamorolone, 6 mg/kg per day. MAIN OUTCOMES AND MEASURES: Study outcomes monitored (1) efficacy, which included motor outcomes (primary: time to stand from supine velocity in the vamorolone, 6 mg/kg per day, group vs placebo; secondary: time to stand from supine velocity [vamorolone, 2 mg/kg per day], 6-minute walk distance, time to run/walk 10 m [vamorolone, 2 and 6 mg/kg per day]; exploratory: NorthStar Ambulatory Assessment, time to climb 4 stairs) and (2) safety, which included growth, bone biomarkers, and a corticotropin (ACTH)-challenge test. RESULTS: Among the 133 boys with DMD enrolled in the study (mean [SD] age, 5.4 [0.9] years), 121 were randomly assigned to treatment groups, and 114 completed the 24-week treatment period. The trial met the primary end point for change from baseline to week 24 time to stand velocity for vamorolone, 6 mg/kg per day (least-squares mean [SE] velocity, 0.05 [0.01] m/s vs placebo -0.01 [0.01] m/s; 95% CI, 0.02-0.10; P = .002) and the first 4 sequential secondary end points: time to stand velocity, vamorolone, 2 mg/kg per day, vs placebo; 6-minute walk test, vamorolone, 6 mg/kg per day, vs placebo; 6-minute walk test, vamorolone, 2 mg/kg per day, vs placebo; and time to run/walk 10 m velocity, vamorolone, 6 mg/kg per day, vs placebo. Height percentile declined in prednisone-treated (not vamorolone-treated) participants (change from baseline [SD]: prednisone, -1.88 [8.81] percentile vs vamorolone, 6 mg/kg per day, +3.86 [6.16] percentile; P = .02). Bone turnover markers declined with prednisone but not with vamorolone. Boys with DMD at baseline showed low ACTH-stimulated cortisol and high incidence of adrenal insufficiency. All 3 treatment groups led to increased adrenal insufficiency. CONCLUSIONS AND RELEVANCE: In this pivotal randomized clinical trial, vamorolone was shown to be effective and safe in the treatment of boys with DMD over a 24-week treatment period. Vamorolone may be a safer alternative than prednisone in this disease, in which long-term corticosteroid use is the standard of care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03439670.
引用
- Guglieri M, Clemens PR, Perlman SJ, et al. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 36036925. doi:10.1001/jamaneurol.2022.2480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。